Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Nineteen House Dems Plan To Vote Against Health Reform If Abortion Funding Is Included
Nineteen House Democrats recently sent a letter to House Speaker Nancy Pelosi (D-Calif.) stating that they will not vote for health care reform legislation "unless it explicitly excludes abortion funding from the scope of any government-defined or subsidized health insurance plan," CongressDaily reports. In the letter, the lawmakers wrote that they want to ensure that the Health Benefits Advisory Committee cannot recommend that abortion services be included as part of benefits packages. They wrote, "Without an explicit exclusion, abortion could be included in a government-subsidized health care plan under general health care." The letter was signed by Reps. Dan Boren (Okla.), Bobby Bright (Ala.), Travis Childers (Miss.), Jerry Costello (Ill.), Lincoln Davis (Tenn.), Kathleen Dahlkemper (Pa.), Steve Driehaus (Ohio), Tim Holden (Pa.), Paul Kanjorski (Pa.), Marcy Kaptur (Ohio), Mike McIntyre (N.C.), Charlie Melancon (La.), John Murtha (Pa.), James Oberstar (Minn.), Solomon Ortiz (Texas), Collin Peterson (Minn.), Heath Shuler (N.C.), Bart Stupak (Mich.) and Gene Taylor (Miss.) (CongressDaily, 6/30).
generic viagra online
More Hysterectomies Could Be Performed With Minimally Invasive Techniques
Eighty percent of women who have a hysterectomy have a traditional one, in which a surgeon must make an extensive incision that runs from the navel to the top of the pubic bone. If only these women"s gynecologists had been trained in minimally invasive laparoscopic surgery techniques, many of them could have had hysterectomies involving just a few small, keyhole incisions. Also, their recovery time would have also been reduced drastically, permitting them to resume their normal lives much faster.
News of the day
Group Health Cooperative Shows Investing In More Primary Care Pays For Itself
An evaluation of recent innovations in delivering primary care at a Group Health Cooperative medical center shows significant success and rapid return on investment. The data led to a decision to invest in these best practices in all of Group Health"s 26 medical centers by 2010.
Diagnostics

Trinity Biotech Announces TRI-statTM CLIA Submission To FDA

Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced it has submitted its CLIA application for its TRI-stat™ point-of-care HbA1c product to the FDA. TRI-stat™ is designed to measure HbA1c, also known as glycated hemoglobin, a measure of a patient"s average blood sugar control over the last two to three months. The availability of TRI-stat™ will improve overall efficiency of diabetes care by delivering HbA1c values during the patient"s visit to the doctor"s office. Utilizing a patented boronate affinity and two-phase optical system, together with a simple, fully automated, plug-and-play instrument design, TRI-stat™ offers highly accurate results in minutes while eliminating the need for refrigeration found with the other three competing products. Diabetes is the fourth leading cause of death by disease in the world. According to the International Diabetes Federation, the number of people diagnosed with type 2 diabetes worldwide has increased from 30 million to more than 246 million over the last two decades. This figure is projected to increase further to 380 million by 2025. In the U.S., some 20.8 million Americans (7 percent of the population) have the disease with a further 54 million Americans considered to be pre-diabetic. The test will allow Trinity to address a doctors" office global market of approximately $200 million. Commenting on the news, Ronan O"Caoimh, CEO, said, "Following the successful completion of our CLIA trials in four independent sites in the USA, I am delighted to announce the submission of our TRI-stat™ CLIA application to the FDA. The test will allow us to address a market which continues to grow significantly each year due to the need for decentralisation of testing to doctors" offices, the recommendations from the American Diabetes Association and the International Diabetes Federation for more frequent patient monitoring and the ongoing increase in the prevalence of diabetes. We will be showcasing the product at the AACC Clinical Lab Expo in Chicago on 21-23 July, 2009." Trinity Biotech


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009